Arena Pharmaceuticals, Inc.  

(Public, NASDAQ:ARNA)   Watch this stock  
Find more results for ARNA
-0.13 (-5.44%)
After Hours: 2.31 +0.05 (2.21%)
Dec 1, 7:09PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.20 - 2.68
52 week 1.60 - 6.28
Open 2.63
Vol / Avg. 6.46M/3.42M
Mkt cap 521.48M
P/E     -
Div/yield     -
EPS -0.47
Shares 242.55M
Beta -0.95
Inst. own 59%
Feb 29, 2016
Q4 2015 Arena Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Dec 3, 2015
Arena Pharmaceuticals Inc Investor Day - 12:00PM EST - Add to calendar
Dec 2, 2015
Arena Pharmaceuticals Inc at Piper Jaffray Healthcare Conference - 8:30AM EST - Add to calendar
Nov 10, 2015
Q3 2015 Arena Pharmaceuticals Inc Earnings Call - Webcast
Nov 10, 2015
Q3 2015 Arena Pharmaceuticals Inc Earnings Release
Sep 9, 2015
Arena Pharmaceuticals Inc at Wells Fargo Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -289.10% -163.67%
Operating margin -275.56% -284.75%
EBITD margin - -259.97%
Return on average assets -34.45% -19.64%
Return on average equity -111.80% -86.94%
Employees 325 -
CDP Score - -


6154 Nancy Ridge Dr
SAN DIEGO, CA 92121-3223
United States - Map
+1-858-4537200 (Phone)
+1-858-4537210 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Arena Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing drugs that target G protein-coupled receptors (GPCRs). The Company's drug, BELVIQ (lorcaserin HCl), was approved by the United States Food and Drug Administration for marketing in the United States. In addition to BELVIQ, the Company has other drug candidates and compounds at various stages of research and development. The Company is exploring lorcaserin's once-a-day, extended release formulation, as an aid to smoking cessation, in combination with phentermine and other agents for weight management, and for other possible indications. The Company's other drug candidates include ralinepag for vascular diseases, APD334 for autoimmune diseases, APD371 for pain and fibrotic diseases, and temanogrel for thrombotic diseases.

Officers and directors

Harry F. Hixson Jr., Ph.D. Interim Chief Executive Officer, Interim principal Financial Officer, Director
Age: 77
Bio & Compensation  - Reuters
Dominic P. Behan Ph.D. Executive Vice President, Chief Scientific Officer, Director
Age: 51
Bio & Compensation  - Reuters
Steven W. Spector J.D. Executive Vice President, General Counsel, Secretary
Age: 50
Bio & Compensation  - Reuters
Craig M. Audet Ph.D. Senior Vice President - Operations and Head of Global Regulatory Affairs
Age: 51
Bio & Compensation  - Reuters
William R. Shanahan Jr., M.D., J.D. Senior Vice President, Chief Medical Officer
Age: 66
Bio & Compensation  - Reuters
Jennifer Kathleen Bielasz Vice President - Accounting, Controller, Principal Accounting Officer
Age: 52
Bio & Compensation  - Reuters
Christine Anna White M.D. Lead Independent Director
Age: 63
Bio & Compensation  - Reuters
Donald D. Belcher Independent Director
Age: 76
Bio & Compensation  - Reuters
Scott H. Bice Independent Director
Age: 68
Bio & Compensation  - Reuters
Tina Susan Nova Ph.D. Independent Director
Age: 62
Bio & Compensation  - Reuters